- Home
- SLS vs CGBD Comparison
SLS vs CGBD Comparison
Compare SLS & CGBD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SLS | CGBD |
|---|---|---|
| Founded | 2012 | 2012 |
| Country | United States | United States |
| Employees | N/A | 2500 |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 924.5M | 761.7M |
| IPO Year | 2007 | N/A |
Fundamental Metrics
Financial Performance| Metric | SLS | CGBD |
|---|---|---|
| Price | $8.12 | $10.90 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 1 | 8 |
| Target Price | $10.00 | ★ $12.92 |
| AVG Volume (30 Days) | ★ 9.0M | 466.8K |
| Earning Date | 05-11-2026 | 05-11-2026 |
| Dividend Yield | N/A | ★ 14.42% |
| EPS Growth | ★ 50.00 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $3.74 |
| Revenue Next Year | $110.98 | $1.80 |
| P/E Ratio | ★ N/A | $10.36 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.39 | $10.48 |
| 52 Week High | $9.51 | $14.32 |
Technical Indicators
Market Signals| Indicator | SLS | CGBD |
|---|---|---|
| Relative Strength Index (RSI) | 55.24 | 45.77 |
| Support Level | $7.07 | $10.61 |
| Resistance Level | $9.51 | $11.10 |
| Average True Range (ATR) | 0.66 | 0.23 |
| MACD | -0.16 | 0.03 |
| Stochastic Oscillator | 44.27 | 49.44 |
Price Performance
Historical ComparisonAbout SLS SELLAS Life Sciences Group Inc.
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.
About CGBD Carlyle Secured Lending Inc.
Carlyle Secured Lending Inc is a specialty finance company that is a closed-end, externally managed, non-diversified management investment company. It focuses on providing directly originated, financing solutions across the capital structure, with a focus on senior secured lending to middle-market companies located in the United States. The company's investment objective is to generate current income and capital appreciation through debt investments in U.S. middle-market companies.